Targovax receives approval to proceed with the ONCOS-102 phase 2 melanoma study from the US FDA
· The US Food and Drug Administration (FDA) has reviewed and accepted the protocol for the ONCOS-102 phase 2 combination trial in PD-1 checkpoint inhibitor (CPI) refractory advanced melanoma · The study is on track to start in late 2022 or early 2023Oslo, Norway, 27 September 2022 – Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target solid tumors, today announces that the FDA has accepted the protocol and given the formal go-ahead to proceed with the planned ONCOS-102 phase 2 trial in melanoma. Study initiation activities are